Disc Medicine (NASDAQ: IRON) Stock Soars on Positive Bitopertin Trial Results and Analyst Upgrade

• BMO Capital has raised its price target for Disc Medicine to $120 from $100, maintaining an Outperform rating on the biotechnology stock.
• Positive Phase 3 clinical trial results for bitopertin in erythropoietic protoporphyria met both primary endpoints, demonstrating efficacy and a favorable safety profile.
• Disc Medicine plans to resubmit its drug application to the FDA by the end of 2026, with an FDA decision anticipated by mid-2027.

The stock of Disc Medicine (NASDAQ: IRON), a rare diseases drug developer, is gaining momentum. BMO Capital maintains its Outperform rating and raises its price target to $120 from $100. The stock stands at $79.12 when the action is posted. An Outperform rating means BMO expects the shares to do better than the broader market, signaling a positive investment outlook for this biotechnology stock.

The higher price target follows positive results from Disc Medicine’s late-stage trial of bitopertin, as highlighted by Reuters. The drug is being studied in adults and adolescents with erythropoietic protoporphyria, including X-linked protoporphyria. These rare conditions can cause painful reactions to light, making effective erythropoietic protoporphyria treatment crucial.

Disc Medicine says its Phase 3 APOLLO trial meets both main goals: lowering protoporphyrin IX, a substance linked to the condition, and increasing the time patients can spend in light. It also reports fewer light-triggered reactions and better measures of light tolerance. Bitopertin is generally well tolerated, with no new safety concerns reported, reinforcing the drug's safety profile and potential for FDA approval.

The clinical trial results support Disc Medicine’s plan to resubmit its drug application to the FDA by the end of 2026. The company expects an FDA decision by mid-2027. Approval is not yet certain; the agency still needs to review the application as part of the rigorous FDA approval process.

Disc Medicine stock trades at $78.62, up $21.78, or 38.32%. That price is below BMO’s new $120 target, though a price target is an analyst estimate, not a guaranteed future price. The shares have traded between $69.98 and $80.33 today, reflecting significant stock performance following the positive news.